版本:
中国

BRIEF-Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy

April 3 Audentes Therapeutics Inc

* Audentes Therapeutics announces FDA clearance of investigational new drug application for AT132 to treat x-linked myotubular myopathy

* Audentes Therapeutics Inc - preliminary data from Aspiro is expected to be available in Q4 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐